Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Simple Summary Acute myelogenous leukemia is an aggressive heterogeneous
hematologic malignancy, and its diagnosis, classification, and treatment have undergone …

The treatment landscape of acute myeloid leukaemia (AML) is evolving rapidly. Venetoclax
in combination with intensive chemotherapy or doublets or triplets with targeted or immune …

Simple Summary FLT3 mutation is commonly present in newly diagnosed patients with
acute myeloid leukemia, and confers high relapse risk. Targeted therapies with FLT3 …

Measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) has an
established role in disease prognostication, particularly in guiding decisions for …

Simple Summary The DEAD-box RNA helicase 41, DDX41, is one of the most frequently
identified mutations in myeloid neoplasms with germline predispositions, which represents …

Patients with TP53 aberrations comprise the highest risk subset of all myeloid malignancies.
The managerial conundrum of TP53-mutant myelodysplastic neoplasms (MDS) and acute …

Acute myeloid leukaemia (AML) is a heterogeneous disease with one of the worst survival
rates of all cancers. The bone marrow microenvironment is increasingly being recognised as …

Highlights•Bone marrow niche is a dynamic structure that plays a main role in
leukemogenesis.•Early cellular senescence severely alters the microenvironment.• …

Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which
has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia …